AVTE

Jade Biosciences Inc. (AVTE) | Rumor.io

Jade Biosciences

AVTE

Attention (50-day avg)0%

Attention rank (50-day avg)#4,551

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization415.9M

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-69.6M

Social

What share of all stock conversation is about AVTE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Apr 24

Aerovate Therapeutics, Inc. (AVTE) has a small cap swing trade idea with a target range of $2.50-2.70.
AVTE has announced a special dividend payment of $2.40 per share, to be distributed on April 29 to shareholders of record on April 25.
The stock has reached premarket highs of $4.35.

Generated by AI

Sentiment

Of the messages about AVTE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	5% -88.24
Bearish	—	—	—	95% +88.24

Jun 17

$AVTE's pulmonary arterial hypertension drug failed phase 2 trials, causing a 93% price drop.
Insiders own only 0.03% of the company, while institutions own 104%, and the company has $99 million in cash, making it potentially attractive for a buyback.
The company is halting enrollment in its phase 3 trial and has significant liabilities and potential for further dilution, making it a potentially undervalued but still bearish investment.

Generated by AI

Topics

Of the messages about AVTE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.43%	75%
Controversies	—	0%	28.57%	25%
Analysts	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0%

Jun 30

Aerovate Therapeutics (AVTE) priced an upsized IPO at $14.00, debuting on Wednesday with 8.7 million shares.
The company, which develops an inhalable version of imatinib for PAH, raised $121.5 million at a post-money valuation of $323.5 million.
Aerovate Therapeutics shares surged 69% in their first day of trading, opening at $28.00 after being priced at $14.00.

Generated by AI

Community

Of the messages about AVTE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	40%	29.27%
Newcomers	—	100%	60%	70.73%

Regulars· Jun 17

Aerovate Therapeutics' AV-101 treatment failed to meet the primary endpoint for pulmonary arterial hypertension in the IMPAHCT trial.
The company's shares lost 91% in premarket trading, with the stock being halted for the first time.
The float rotation of Aerovate Therapeutics' shares has elevated squeeze potential, with a gain of 22.2% and a float of 17.0M.

Newcomers· Jun 21

Newcomers are excited about the potential for Aerovate Therapeutics' ($AVTE) #imatinib to have greater potency and fewer side effects compared to other treatments, citing a $1.70 cash value and insiders' buying activity.
The CFO and CCO of a related company ($GOSS) have made recent significant purchases, and the timing of these transactions coincides with Aerovate Therapeutics' recent failure and a completed deal with Chiesi.
New investors are taking note of Aerovate Therapeutics' strong cash position ($3.47/share) and lack of debt, with RA Capital increasing its stake, and some believe the company's recent price drop from $25 to $1 may be too good to ignore.

Generated by AI

Also Discussed

Investors talking about AVTE also mention

#	Name	Attention
1	IGMS - IGM Biosciences, Inc.	——
2	PMV Pharmaceuticals, Inc.PMVP	0%0
3	Gossamer Bio Inc.GOSS	0%+0
4	E-Home Household Service Holdings Ltd.EJH	0%new
5	Genelux CorporationGNLX	0%0
6	Barnes & Noble Education Inc.BNED	0%0
7	ImageneBio, Inc.IKNA	0%0
8	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
9	GH Research PLCGHRS	0%0
10	BeneficientBENF	0.01%+0

Jade Biosciences Inc.

Healthcare
Biotechnology

Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its current pipeline centers on antibody-based programs designed to target key immune pathways involved in conditions such as immunoglobulin A nephropathy and other inflammation-related disorders. The company’s lead candidate, JADE101, is being developed to inhibit APRIL, a protein linked to abnormal immune activity, while JADE201 and JADE301 are advancing through earlier-stage research for additional autoimmune indications. Jade Biosciences works as a development-focused biopharmaceutical company, relying on clinical research, preclinical testing, and collaboration agreements to advance its programs. Headquartered in Waltham, Massachusetts, the company serves the immunology and nephrology fields by pursuing targeted biologic therapies for patients with significant unmet medical needs.

Website

Location

Building 23

Waltham, MA, 02453

United States

Social

What share of all stock conversation is about AVTE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Apr 24

Aerovate Therapeutics, Inc. (AVTE) has a small cap swing trade idea with a target range of $2.50-2.70.
AVTE has announced a special dividend payment of $2.40 per share, to be distributed on April 29 to shareholders of record on April 25.
The stock has reached premarket highs of $4.35.

Generated by AI

Sentiment

Of the messages about AVTE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	5% -88.24
Bearish	—	—	—	95% +88.24

Jun 17

$AVTE's pulmonary arterial hypertension drug failed phase 2 trials, causing a 93% price drop.
Insiders own only 0.03% of the company, while institutions own 104%, and the company has $99 million in cash, making it potentially attractive for a buyback.
The company is halting enrollment in its phase 3 trial and has significant liabilities and potential for further dilution, making it a potentially undervalued but still bearish investment.

Generated by AI

Topics

Of the messages about AVTE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.43%	75%
Controversies	—	0%	28.57%	25%
Analysts	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0%

Jun 30

Aerovate Therapeutics (AVTE) priced an upsized IPO at $14.00, debuting on Wednesday with 8.7 million shares.
The company, which develops an inhalable version of imatinib for PAH, raised $121.5 million at a post-money valuation of $323.5 million.
Aerovate Therapeutics shares surged 69% in their first day of trading, opening at $28.00 after being priced at $14.00.

Generated by AI

Community

Of the messages about AVTE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	40%	29.27%
Newcomers	—	100%	60%	70.73%

Regulars· Jun 17

Aerovate Therapeutics' AV-101 treatment failed to meet the primary endpoint for pulmonary arterial hypertension in the IMPAHCT trial.
The company's shares lost 91% in premarket trading, with the stock being halted for the first time.
The float rotation of Aerovate Therapeutics' shares has elevated squeeze potential, with a gain of 22.2% and a float of 17.0M.

Newcomers· Jun 21

Newcomers are excited about the potential for Aerovate Therapeutics' ($AVTE) #imatinib to have greater potency and fewer side effects compared to other treatments, citing a $1.70 cash value and insiders' buying activity.
The CFO and CCO of a related company ($GOSS) have made recent significant purchases, and the timing of these transactions coincides with Aerovate Therapeutics' recent failure and a completed deal with Chiesi.
New investors are taking note of Aerovate Therapeutics' strong cash position ($3.47/share) and lack of debt, with RA Capital increasing its stake, and some believe the company's recent price drop from $25 to $1 may be too good to ignore.

Generated by AI

Jade Biosciences

Social

Apr 24

Sentiment

Jun 17

Topics

Jun 30

Community

Regulars· Jun 17

Newcomers· Jun 21

Also Discussed

Jade Biosciences Inc.

Company Information

Location

Also Discussed

Social

Apr 24

Sentiment

Jun 17

Topics

Jun 30

Community

Regulars· Jun 17

Newcomers· Jun 21